SLC19A3 and Wernicke encephalopathy: Follow-up in vitro studies revealed that fedratinib is a THTR2 substrate and inhibitor at low, clinically relevant concentrations (Table 2), which would diminish thiamine absorption through enterocytes and promote Wernicke’s encephalopathy [29].